Rituximab

Rituxan met a primary endpoint and demonstrated it is superior to mycophenolate mofetil in adults with moderate to severe pemphigus vulgaris in the phase 3 PEMPHIX study, which was presented at the European Academy of Dermatology and Venereology Congress.

SAN DIEGO — Increasing use of checkpoint inhibitors in cancer therapy is leading to an uptick in immune-related adverse events for rheumatologists to manage, according to a presentation at the Congress of Clinical Rheumatology West.

SAN DIEGO — A recent FDA approval for systemic sclerosis-associated interstitial lung diseases may portend a new hope for clinicians managing these complicated disorders, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

SAN DIEGO — Rheumatologists treating patients with lupus nephritis should make a concerted effort to reduce or avoid use of NSAIDs and other nephrotoxic drugs in order to improve long-term outcomes, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

GRAND RAPIDS, Mich. — As infusion centers have grown in complexity throughout the years, so too has the patient experience in these suites, with individuals often asked to take on a greater understanding of the clinical and financial impacts of their treatment, according to a presenter at the National Organization of Rheumatology Managers Annual Conference.

Infusion reaction rates to rituximab may be more significant among patients with systemic lupus erythematosus than other diseases, according to findings published in BMC Rheumatology.

Upfront autologous hematopoietic stem cell transplantation consolidation did not appear to benefit patients with aggressive B-cell non-Hodgkin lymphoma, according to results of a meta-analysis published in Cancer.

The combination of ibrutinib, lenalidomide and rituximab demonstrated robust, ongoing activity among patients with relapsed or refractory diffuse large B-cell lymphoma, especially those with nongerminal center B-cell DLBCL, according to results of the dose-escalation portion of a phase 1b/phase 2 study published in Blood.

This May, more than 100 fellows and junior faculty members flocked to the 2019 North American Young Rheumatology Investigator Forum held in Destin, Fla., where they presented their original research in oral and poster sessions.

Adjuvant low-dose rituximab in combination with plasma exchange and steroids appeared effective for the treatment of acquired thrombotic thrombocytopenic purpura, according to results of a prospective, single-arm phase 2 study published in Blood.